Clinical Trial Search

Primary: Calculation of M Scores and HCC Probability Scores — 1.113; 1.159; 1.797; 1.707 units on a scale

Primary: Number of Patients With DLTs — 0; 2; 1; 0 Participants

Primary: Number of Subjects With Overall Survival — 16; 4; 34; 24 Participants — p=0.536

Primary: Time to Progression (TTP) — 164; 112 days

Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months

Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM

Primary: 3-year Survival Without Tumor Progression for Patients Within the Milan Criteria — 60 percentage of participants

Primary: Disease Control Rate (DCR) at 16 Weeks for Patients Treated With Guadecitabine After Failure of Sorafenib — 25.0; 24.4 percentage of patients

Primary: Overall Survival — 289; 259 Days

Primary: Number of Participants With Objective Response Rate — 20; 9; 0; 1 Participants

Primary: Number of Participants Who Remained Free of Progression at the 27th Week. — 21 participants — p=0.0006

Primary: Tumour Non-recurrence Rate — 32; 40; 35 Participants — p=0.072

Primary: Dose Limiting Toxicity — 0; 0; 0 Participants

Primary: Correlation Between the Growth Speeds of the Cultured Cells and the AJCC TNM Stage (7th Eds) at Entering of the Study. — 21; 29; 14; 9 participants — p=< 0.005

Primary: Disease Control Rate (DCR) — 0; 0; 9 Participants

Primary: Progression-Free Survival(PFS) — 5.7; 2.7 months — p=<0.001

Primary: HCC Screening Completion — 27.6; 54.5; 54.1 Percentage of participants

Primary: Participants Without Recurrence (Disease-free). — 16; 28 Participants

Primary: Overall Survival (OS) — 8.51; 7.29 Months — p=0.0199

Primary: One-Year Overall Survival Rate — 16 Participants

Primary: Percentage of Participants for Each Type of Response — 0; 2.2; 5.8; 54.7 percentage of participants

Primary: The Percentage of Patients With Local Control at 1 Year Post Treatment — 99 percentage of patients

Primary: Proportion of Subjects Achieving Disease Control (Non-progressive Disease) at 8 Weeks After Initiation of Treatment — 0.7273; 0.6429 Proportion of evaluable participants

Primary: Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity — 0; 0; 0 Participants

Primary: Overall Survival (OS) — 324; 241 days — p=0.00583

Primary: Blood Volume (BV) According to Degree of Lesions Differentiation — 15.930; 13.958 mL/100 grams

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability. — 16; 5 Participants

Primary: SubStudy 1: Apparent Diffusion Coefficient (ADC) — 1.43 1x10^-3 mm^2/s

Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC) — 15 mg/kg

Primary: Time to Disease Progression — 8 months